$225 Million

Array Biopharmaceuticals

Follow-on Offering

Bookrunner, September 2017

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s late stage programs include binimetinib and encorafenib for the treatment of melanoma and colorectal cancer, selumetinib (partnered with AstraZeneca) for the treatment of lung cancer and thyroid cancer, danoprevir (partnered with Roche) for the treatment of hepatitis C and ipatsertib (partnered with Genentech) for the treatment of prostate cancer, breast cancer and gastric cancer.